Natural History of Wilson Disease

计划入组 300 人 · 首次发布于 2017 年 11 月 7 日

Early Access Program for ALXN1840 in Patients With Wilson Disease

首次发布于 2023 年 1 月 17 日

Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease

计划入组 8 人 · 首次发布于 2011 年 11 月 17 日

ATP7B gene therapy (AAV, Wilson Disease)

ATP7B gene therapy (AAV5, Wilson disease)

ATP7B gene therapy (TetraVecta/lentiviral vector, Wilson disease)

Wilson Therapeutics AB

Sweden

Wilson Products Compressed Gas Co.

United States

WILSON TRADING COMPANY LIMITED

Hong Kong, China

Monopar's ALXN1840 Shows Sustained Neurological Benefits in Long-Term Wilson Disease Study

Orphalan Initiates Global Phase 3 TRADITiONAL Study of Once-Daily Trientine in Wilson Disease

Eton Pharmaceuticals Launches FDA-Approved Galzin for Wilson Disease Maintenance Treatment